Strategic Global Advisors LLC Buys Shares of 97,747 Exelixis, Inc. $EXEL

Strategic Global Advisors LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, according to its most recent filing with the SEC. The firm purchased 97,747 shares of the biotechnology company’s stock, valued at approximately $5,318,000.

Several other large investors have also recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. boosted its position in Exelixis by 0.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after purchasing an additional 281 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of Exelixis by 5.8% during the 4th quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 298 shares in the last quarter. Cim LLC raised its stake in shares of Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after acquiring an additional 305 shares in the last quarter. J.W. Cole Advisors Inc. lifted its position in Exelixis by 6.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 329 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its position in Exelixis by 3.8% during the first quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock valued at $389,000 after acquiring an additional 333 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Trading Down 1.1%

NASDAQ:EXEL opened at $56.10 on Thursday. The company has a market cap of $13.90 billion, a PE ratio of 17.64, a P/E/G ratio of 1.69 and a beta of 0.44. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $57.57. The company’s 50 day moving average is $54.46 and its two-hundred day moving average is $48.88.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. Exelixis’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.75 EPS. As a group, analysts expect that Exelixis, Inc. will post 3.18 EPS for the current fiscal year.

Insider Activity

In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of Exelixis stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $50.14, for a total value of $491,973.68. Following the sale, the director owned 16,079 shares in the company, valued at approximately $806,201.06. The trade was a 37.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,549 shares of company stock valued at $1,216,894 over the last ninety days. 2.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on EXEL shares. TD Cowen lifted their price target on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Stifel Nicolaus increased their price objective on Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Morgan Stanley raised their price objective on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 23rd. Royal Bank Of Canada boosted their target price on Exelixis from $43.00 to $46.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Barclays upped their target price on Exelixis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $50.07.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.